Making ivermectin available over the counter in West Virginia
Summary
House Bill 2938 would amend West Virginia’s controlled substances and drug scheduling laws to expressly allow ivermectin to be sold, dispensed by a pharmacist or pharmacy over the counter, or possessed without a prescription. The bill creates a new section in Chapter 60A of the West Virginia Code stating that, notwithstanding any other provision of that chapter, ivermectin may be made available without a prescription.
In practical terms, the measure would remove any state-law barrier in the controlled substances framework to nonprescription access to ivermectin. It does not describe dosage limits, age restrictions, labeling requirements, or other regulatory conditions, and it does not appear to change federal law or FDA rules; rather, it would affect how ivermectin may be handled under West Virginia law by pharmacies, pharmacists, sellers, and consumers.
Impact
The bill would add a new section, §60A-2-204a, to West Virginia’s drug scheduling statutes and carve ivermectin out for over-the-counter sale, dispensing, and possession without a prescription. This would directly affect pharmacists, pharmacies, retailers, and individuals by authorizing nonprescription access under state law and reducing the legal need for a physician’s prescription for ivermectin in West Virginia.
Sentiment
Based on the bill text and available context, the measure appears to be introduced in a straightforward, permissive form with no recorded committee debate or vote history provided. The overall sentiment cannot be measured from transcripts or votes, but the bill’s sponsors and caption indicate support for making ivermectin more readily available over the counter.
Contention
No committee testimony, amendments, or recorded votes are included, so specific points of contention are not documented in the available materials. The likely policy divide, based on the subject matter, would be between supporters of expanded access to ivermectin and those concerned about safety, appropriate medical oversight, or consistency with existing drug regulation, but those concerns are not explicitly stated in the provided record.